Wall Street Optimism Spills Over to These 10 Stocks on Friday

3. Immunitybio Inc. (NASDAQ:IBRX)

Immunitybio snapped a six-day losing streak on Friday as investors resorted to bargain-hunting to take advantage of its cheap valuation while also cheering news that it has officially received the Food and Drug Administration’s (FDA) Regenerative Medicine Advanced Therapy designation for ANKTIVA and CARNK to treat lymphopenia and pancreatic cancer.

In other news, earlier last month, IBRX was also authorized by the FDA to help address the supply shortage of bladder cancer treatments in the US through bringing a vital alternative source of BCG (Bacillus Calmette-Guérin).

Upon securing FDA approval, IBRX said supplies of rBCG would be shipped immediately. The alternative source was developed by the Serum Institute of India, the world’s largest manufacturer of vaccines by volume.

Data from the National Cancer Institute in 2024 showed that there were 83,190 estimated new cases of bladder cancer in the US, while 16,840 died from the disease during the period. The current survival rate for individuals with bladder cancer is 78.4 percent.